Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2014

01.05.2014 | Epidemiology

Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations

verfasst von: D. Amadori, P. Serra, S. Bravaccini, A. Farolfi, M. Puccetti, E. Carretta, L. Medri, O. Nanni, M. M. Tumedei, J. Kahima, N. Masalu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Information on hormone receptor and human epidermal growth factor receptor-2 (HER2) expression in breast cancer is acknowledged as mandatory for prognostic stratification and treatment planning. Data on the biological features of African breast cancers are poor. We decided to compare histopathological and biomolecular characteristics (estrogen and progesterone receptor—ER, PgR, and HER2) of Tanzanian and Italian breast cancers. Differences in proliferating index and androgen receptor (AR) expression in triple-negative patients from the two case series were also assessed. Of the 103 consecutive patients seen at the Bugando Medical Center (Mwanza, Tanzania) from 2003 to 2010, who underwent biopsy or surgical resection of primary breast cancer, 69 patients had tissue samples that were evaluable for estrogen receptor (ER), progesterone receptor (PgR), and HER2. Histopathological assessment and biomolecular determinations were performed at the Cancer Institute of Romagna (IRST IRCCS, Meldola, Italy). Caucasian breast cancers were randomly extracted from an electronic database and matched (1:2 ratio) for year of diagnosis and age at diagnosis. Median age of both populations was 51 years (range 27–84). With respect to Caucasian tumors, Tanzanian breast cancers at diagnosis more frequently showed high histological grade (mainly grade 3) (P = 0.03), advanced clinical stage (III or IV) (P < 0.001), ER negativity (52.2 %, P < 0.001) and high proliferation (P = 0.0002). Triple-negative tumors were over-represented in Tanzanian women. AR was positive in 38.5 and 38 % of triple-negative Tanzanian and Italian breast cancers, respectively. Our results show that histopathological and biomolecular characteristics in Tanzanian and Italian breast cancers differ substantially. The high frequency of poorly differentiated, ER-negative, highly proliferating tumors, together with advanced stage at presentation, could be considered as the main prognostic factors linked to the high mortality rates for breast cancer in the African population.
Literatur
2.
Zurück zum Zitat O Morhason-Bello I, Odedina F, Rebbeck TR, Harford J, Dangou JM, Denny L, Adewole IF (2013) Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. Lancet Oncol 14:e142–e151. doi:10.1016/S1470-2045(12)70482-5 CrossRef O Morhason-Bello I, Odedina F, Rebbeck TR, Harford J, Dangou JM, Denny L, Adewole IF (2013) Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. Lancet Oncol 14:e142–e151. doi:10.​1016/​S1470-2045(12)70482-5 CrossRef
3.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 24:2206–2223. doi:10.1093/annonc/mdt303 PubMedCentralPubMedCrossRef Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 24:2206–2223. doi:10.​1093/​annonc/​mdt303 PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI (2008) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521. doi:10.1200/JCO.19.6873 CrossRef Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI (2008) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521. doi:10.​1200/​JCO.​19.​6873 CrossRef
5.
Zurück zum Zitat Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L (2010) African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 116:4926–4932. doi:10.1002/cncr.25276 PubMedCentralPubMedCrossRef Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L (2010) African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 116:4926–4932. doi:10.​1002/​cncr.​25276 PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, Oyebadejo TY, Banjo AA, Deji-Agboola AM, Rakha EA, Green AR, Ellis IO (2012) Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat 135:555–569. doi:10.1007/s10549-012-2173-7 PubMedCrossRef Agboola AJ, Musa AA, Wanangwa N, Abdel-Fatah T, Nolan CC, Ayoade BA, Oyebadejo TY, Banjo AA, Deji-Agboola AM, Rakha EA, Green AR, Ellis IO (2012) Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat 135:555–569. doi:10.​1007/​s10549-012-2173-7 PubMedCrossRef
8.
Zurück zum Zitat Amadori D, Masalu N, Nanni O, Bravaccini S, Puccetti M, Tumino R, Kaima J, Serra P (2013) “Vanda project”: a screening program for cervical and breast cancer in tanzania. Data collection, monitoring and analysis. Tumori 14:S6 Amadori D, Masalu N, Nanni O, Bravaccini S, Puccetti M, Tumino R, Kaima J, Serra P (2013) “Vanda project”: a screening program for cervical and breast cancer in tanzania. Data collection, monitoring and analysis. Tumori 14:S6
9.
Zurück zum Zitat Mbonde MP, Amir H, Akslen LA, Kitinya JN (2001) Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J 78:360–365PubMedCrossRef Mbonde MP, Amir H, Akslen LA, Kitinya JN (2001) Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J 78:360–365PubMedCrossRef
10.
Zurück zum Zitat Gukas ID, Jennings BA, Mandong BM, Manasseh AN, Harvey I, Leinster SJ (2006) A comparison of the pattern of occurrence of breast cancer in Nigerian and British women. Breast 15:90–95PubMedCrossRef Gukas ID, Jennings BA, Mandong BM, Manasseh AN, Harvey I, Leinster SJ (2006) A comparison of the pattern of occurrence of breast cancer in Nigerian and British women. Breast 15:90–95PubMedCrossRef
11.
Zurück zum Zitat Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor-positive breast cancers. Breast Cancer Res Treat 124:607–617. doi:10.1007/s10549-010-0761-y PubMedCrossRef Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor-positive breast cancers. Breast Cancer Res Treat 124:607–617. doi:10.​1007/​s10549-010-0761-y PubMedCrossRef
12.
Zurück zum Zitat Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22:1755–1762. doi:10.1093/annonc/mdq678 PubMedCrossRef Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22:1755–1762. doi:10.​1093/​annonc/​mdq678 PubMedCrossRef
14.
Zurück zum Zitat Castellano I, Chiusa L, Vandone AM, Beatrice S, Goia M, Donadio M, Arisio R, Muscarà F, Durando A, Viale G, Cassoni P, Sapino A (2013) A simple and reproducible prognostic index in luminal ER-positive breast cancers. Ann Oncol 24:2292–2297. doi:10.1093/annonc/mdt183 PubMedCentralPubMedCrossRef Castellano I, Chiusa L, Vandone AM, Beatrice S, Goia M, Donadio M, Arisio R, Muscarà F, Durando A, Viale G, Cassoni P, Sapino A (2013) A simple and reproducible prognostic index in luminal ER-positive breast cancers. Ann Oncol 24:2292–2297. doi:10.​1093/​annonc/​mdt183 PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Thike AA, Chong LYZ, Cheok PY, Li HH, Yip GWC, Huat Bay B, Tse GM, Iqbal J, Tan PH (2013) Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. doi:10.1038/modpathol.2013.145 PubMed Thike AA, Chong LYZ, Cheok PY, Li HH, Yip GWC, Huat Bay B, Tse GM, Iqbal J, Tan PH (2013) Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. doi:10.​1038/​modpathol.​2013.​145 PubMed
17.
Zurück zum Zitat Amadori D, Silvestrini R (1998) Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 51:267–281PubMedCrossRef Amadori D, Silvestrini R (1998) Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 51:267–281PubMedCrossRef
18.
Zurück zum Zitat Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L (2012) Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 135:619–627. doi:10.1007/s10549-012-2194-2 PubMedCrossRef Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L (2012) Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 135:619–627. doi:10.​1007/​s10549-012-2194-2 PubMedCrossRef
21.
Zurück zum Zitat Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A (2003) HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 21:2708–2712PubMedCrossRef Volpi A, Nanni O, De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A (2003) HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 21:2708–2712PubMedCrossRef
22.
Zurück zum Zitat de Azambuja E, Cardoso F, de Castro G, Jr Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504–1513PubMedCentralPubMedCrossRef de Azambuja E, Cardoso F, de Castro G, Jr Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504–1513PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486. doi:10.1186/1471-2407-11-486 PubMedCentralPubMedCrossRef Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486. doi:10.​1186/​1471-2407-11-486 PubMedCentralPubMedCrossRef
Metadaten
Titel
Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations
verfasst von
D. Amadori
P. Serra
S. Bravaccini
A. Farolfi
M. Puccetti
E. Carretta
L. Medri
O. Nanni
M. M. Tumedei
J. Kahima
N. Masalu
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2903-0

Weitere Artikel der Ausgabe 1/2014

Breast Cancer Research and Treatment 1/2014 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.